LLY

1,093.51

-3.35%↓

JNJ

225.48

-2.31%↓

ABBV

215.94

-1.07%↓

UNH

380.86

-0.12%↓

MRK

119.64

+0.1%↑

LLY

1,093.51

-3.35%↓

JNJ

225.48

-2.31%↓

ABBV

215.94

-1.07%↓

UNH

380.86

-0.12%↓

MRK

119.64

+0.1%↑

LLY

1,093.51

-3.35%↓

JNJ

225.48

-2.31%↓

ABBV

215.94

-1.07%↓

UNH

380.86

-0.12%↓

MRK

119.64

+0.1%↑

LLY

1,093.51

-3.35%↓

JNJ

225.48

-2.31%↓

ABBV

215.94

-1.07%↓

UNH

380.86

-0.12%↓

MRK

119.64

+0.1%↑

LLY

1,093.51

-3.35%↓

JNJ

225.48

-2.31%↓

ABBV

215.94

-1.07%↓

UNH

380.86

-0.12%↓

MRK

119.64

+0.1%↑

Kodu・Aktsiate loetelu・Denali Therapeutics Inc

Denali Therapeutics Inc

Avatud

SektorTervishoid

21.1 2.43

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

20.54

Max

21.16

Põhinäitajad
By Trading Economics
Sissetulek	102K -128M
Aktsiakasum	-0.69
Töötajad	507
EBITDA	-9.8M -135M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+75.66% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	7. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-4.1M 3B
Eelmine avamishind	18.67
Eelmine sulgemishind	21.1

Uudiste sentiment

By Acuity

76%

24%

310 / 344 Pingereas Healthcare

Denali Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

28. mai 2026, 22:47 UTC

Tulu

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

28. mai 2026, 20:45 UTC

Tulu

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

28. mai 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

28. mai 2026, 23:39 UTC

Market Talk

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

28. mai 2026, 23:31 UTC

Market Talk

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

28. mai 2026, 23:17 UTC

Market Talk

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

28. mai 2026, 23:02 UTC

Market Talk

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

28. mai 2026, 22:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28. mai 2026, 22:41 UTC

Market Talk

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

28. mai 2026, 22:37 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

M&A-Related Insurance Payments In North America Rise -- Market Talk

28. mai 2026, 22:04 UTC

Omandamised, ülevõtmised, äriostud

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

28. mai 2026, 22:04 UTC

Omandamised, ülevõtmised, äriostud

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

28. mai 2026, 21:12 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

28. mai 2026, 21:00 UTC

Tulu

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

28. mai 2026, 20:57 UTC

Tulu

Dell Stock Soars on Blowout Earnings -- Barrons.com

28. mai 2026, 20:55 UTC

Tulu

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

28. mai 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

28. mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

28. mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

28. mai 2026, 20:48 UTC

Kuumad aktsiad

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

28. mai 2026, 20:34 UTC

Tulu

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

28. mai 2026, 20:31 UTC

Tulu

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

28. mai 2026, 20:28 UTC

Tulu

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

28. mai 2026, 20:26 UTC

Tulu

Dell Stock Soars on Blowout Earnings -- Barrons.com

28. mai 2026, 20:20 UTC

Tulu

Costco 3Q Membership Fees $1.37B

28. mai 2026, 20:20 UTC

Tulu

Costco 3Q Net Sales $69.15B

28. mai 2026, 20:19 UTC

Tulu

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

28. mai 2026, 20:19 UTC

Tulu

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

28. mai 2026, 20:17 UTC

Tulu

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

28. mai 2026, 20:17 UTC

Tulu

Costco 3Q Same-Store Sales Up 9.8% >COST

Võrdlus sarnastega

Hinnamuutus

Denali Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

75.66% tõus

12 kuu keskmine prognoos

Keskmine 35.5 USD 75.66%

Kõrge 42 USD

Madal 23 USD

Põhineb 13 Wall Streeti analüütiku instrumendi Denali Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

13 ratings

Osta

Hoia

Müü

Põhineb 13 analüütiku instrumendi Denali Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

310 / 344 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.